Dr. Katz's research shows how important it is for all breast cancer survivors to have access to genetic testing services, ...

AAVantgarde Bio has announced the successful closing of a $141 million (€122 million) Series B financing round that was co-led by a new lead, Schroders Capital, as well as existing investors Atlas ...

Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially ...

Prenatal testing revenue in the third quarter of 2025 grew 2% year-over-year, reflecting ongoing expansion of payer coverage, particularly for Foresight Expanded Carrier Screen. Prenatal volume over ...

Embargoed for 9am CET (3am ET) on Monday November 3rdAmgen Ventures-backed AAVantgarde Bio has raised $143 million in series ...

Max Healthcare,one of the largest private sector healthcare services companies in India, andTata Institute for Genetics and Society (TIGS), a leading genomics research institute, today announced the ...

A new genomic method has enabled multiple people with rare conditions to receive diagnoses that were previously unattainable ...

A new genomic method has enabled multiple people with rare conditions to receive diagnoses that were previously unattainable ...

A United States–based Nigerian nurse practitioner and oncology researcher, Edith Declan, has called on the Federal Government ...

For managed care organizations and health systems, the recommendations strongly advocated highly selective use of NGS. Routine, nonselective NGS for all sarcoma patients is not justified. Instead, ...

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated safety and efficacy ...

Lexeo Therapeutics (NASDAQ:LXEO) is one of billionaire Daniel Sundheim’s stock picks with huge upside potential.